CALCULATE YOUR SIP RETURNS

Stocks/Share Market - Angel One

TVS Motor Envisions Growth Amidst Positive Industry Outlook

TVS Motor Envisions Growth Amidst Positive Industry Outlook

7 August 2024

TVS Motor Chairman Ralf Speth expressed optimism about the domestic two-wheeler industry’s growth trajectory for the current fiscal year, driven by factors such as normal rainfall and a resurgence in rural demand. The company anticipates a gradual recovery in export markets, particularly in Africa, Latin America, ASEAN, and the Middle East. Speth highlighted the company’s …

Bata India Reports Mixed Q1 FY25 Results: Revenue Slipped, But Net Profit Soared

Bata India Reports Mixed Q1 FY25 Results: Revenue Slipped, But Net Profit Soared

7 August 2024

Bata India Limited announced its financial results for the quarter ended June 30, 2024. While the company reported a net profit of ₹1,744 million, revenue experienced a slight decline compared to the previous year. The company attributed the results to a combination of factors. A one-time gain of ₹1,340 million from the sale of the …

JM Financial Reports Strong Q1 FY25 Performance

JM Financial Reports Strong Q1 FY25 Performance

7 August 2024

JM Financial Limited announced robust financial results for the first quarter ended June 30, 2024, reflecting growth across key business segments. Key Highlights Strong growth in private wealth and PMS AUM Expansion of retail mortgage lending business Significant increase in platform AWS business Progress in alternative and distressed credit segment Wholesale Credit Business The company …

Fortis Q1 FY25 Financial Results: 39% EBITDA Growth and Expanding Hospital Revenues

Fortis Q1 FY25 Financial Results: 39% EBITDA Growth and Expanding Hospital Revenues

7 August 2024

On August 06, 2024, Fortis Healthcare Ltd, a top healthcare provider in India, released its unaudited financial results for the quarter ending June 30, 2024. As of June 30, 2024, Fortis Healthcare Ltd’s net debt was ₹308 crore, with a Net Debt to EBITDA ratio of 0.22x, down from 0.35x a year earlier. The Net …

Lupin Q1 FY2025 Results: Strong Performance with ₹37,697 Million Gross Profit

Lupin Q1 FY2025 Results: Strong Performance with ₹37,697 Million Gross Profit

7 August 2024

On August 06, 2024, Lupin Limited, a leading pharmaceutical company, announced its financial results for the quarter ending June 30, 2024. Lupin Limited reported a gross profit of ₹37,697 million, up from ₹33,213 million in Q4 FY2024, with a gross margin of 68.4%. Personnel costs amounted to ₹9,710 million, or 17.6% of sales, compared to …

IIFL Finance Reports Mixed Q1 FY25 Results

IIFL Finance Reports Mixed Q1 FY25 Results

7 August 2024

IIFL Finance reported a decline in net profit after tax by 28% YoY to ₹338 crore for Q1 FY25. PBT also decreased by 29% YoY to ₹436 crore. While the company witnessed growth in key segments like home loans and loans against property, the overall performance was impacted by factors such as a decline in …

RAIN Industries Reports Q2 2024: Revenue Down 12.2%, Profit Plummets

RAIN Industries Reports Q2 2024: Revenue Down 12.2%, Profit Plummets

7 August 2024

On August 06, 2024, Rain Industries Limited released its unaudited financial results for the second quarter, which ended on June 30, 2024. Financial Highlights for Q2 2024 RAIN’s revenue from operations was ₹40.94 billion, down from ₹46.27 billion in Q2 2023. The adjusted EBITDA stood at ₹4.90 billion, compared to ₹6.75 billion in the same …

Gabriel India Boosts Stake in TP Solapur Solar Under New Power Arrangement

Gabriel India Boosts Stake in TP Solapur Solar Under New Power Arrangement

7 August 2024

Gabriel India Limited has announced to the stock exchanges that it has entered into a Group Captive Arrangement under the Electricity Act, 2003 and Electricity Rules, 2005. This arrangement involves the establishment of a Group Captive Power Plant by TP Solapur Solar Limited, a Special Purpose Vehicle. The power plant is designed for collective use …

Aurobindo Pharma Gets USFDA Nod for Estradiol Vaginal Inserts

Aurobindo Pharma Gets USFDA Nod for Estradiol Vaginal Inserts

7 August 2024

On August 6, 2024, Aurobindo Pharma Limited announced that it had received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Estradiol Vaginal Inserts USP, 10 mcg. This product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), VAGIFEM® 10 mcg, developed by Novo Nordisk Inc. The company …

G R Infraprojects Wins Bid for Tumkur‐II REZ Transmission Scheme

G R Infraprojects Wins Bid for Tumkur‐II REZ Transmission Scheme

7 August 2024

On August 6, 2024, G R Infraprojects Limited announced that it has emerged as the L-1 bidder for the establishment of the “Transmission Scheme for Integration of Tumkur‐II REZ” in Karnataka. This project was awarded through a tariff-based competitive bidding (TBCB) process on a build, own, operate, and transfer (BOOT) basis. The announcement was made …

Open Free Demat Account!
Enjoy ₹0 Account Opening Charges